Affordable Access

Publisher Website

Preferences for follow up in long-term survivors after cervical cancer.

  • Vistad, Ingvild1, 2
  • Lindemann, Kristina3, 4
  • Bentzen, Anne G5
  • Dahl, Alv A4, 6
  • Steen, Rita7, 8
  • Kiserud, Cecilie6
  • 1 Department of Obstetrics and Gynecology, Sørlandet Hospital Kristiansand, Kristiansand, Norway. , (Norway)
  • 2 Department of Clinical Science, University of Bergen, Bergen, Norway. , (Norway)
  • 3 Department of Gynecologic Oncology, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway. , (Norway)
  • 4 Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. , (Norway)
  • 5 Department of Gynecologic Oncology, University Hospital of North Norway, Tromsø, Norway. , (Norway)
  • 6 National Advisory Unit on Late Effects after Cancer Treatment, Oslo University Hospital, The Norwegian Radium Hospital, Oslo, Norway. , (Norway)
  • 7 Department of Clinical Service, The Cancer Clinic, Oslo University Hospital, Oslo, Norway. , (Norway)
  • 8 Department of Pain Management and Research, Oslo University Hospital, Oslo, Norway. , (Norway)
Published Article
Acta Obstetricia Et Gynecologica Scandinavica
Wiley (Blackwell Publishing)
Publication Date
Sep 01, 2020
DOI: 10.1111/aogs.13855
PMID: 32232835


An increasing number of cervical cancer survivors combined with lack of data on the efficacy of long-term surveillance, challenges existing follow-up models. However, before introducing new follow-up models, cervical cancer survivors' own views on follow up are important. We aimed to explore preferences for follow up in long-term cervical cancer survivors and their associations with self-reported late-effects. In 2013, we mailed 974 Norwegian long-term cervical cancer survivors treated during 2000-2007 a questionnaire with items covering preferences for follow up after treatment, clinical variables and validated questionnaires covering anxiety, neuroticism and depression. We included 471 cervical cancer survivors (response rate 57%) with a median follow up of 11 years. In all, 77% had FIGO stage I disease, and 35% were attending a follow-up program at the time of survey. Of the patients, 55% preferred more than 5 years of follow up. This was also preferred by 57% of cervical cancer survivors who were treated with conization only. In multivariable analyses, chemo-radiotherapy or surgery with radiation and/or chemotherapy (heavy treatment) and younger age were significantly associated with a preference for more than 5 years' follow up. Late effects were reported by more than 70% of the cervical cancer survivors who had undergone heavy treatment. Our study reveals the need for targeted patient education about the benefits and limitations of follow up. To meet increasing costs of cancer care, individualized follow-up procedures adjusted to risk of recurrence and late-effects in cervical cancer survivors are warranted. © The Authors. Acta Obstetricia et Gynecologica Scandinavica published by John Wiley & Sons Ltd on behalf of Nordic Federation of Societies of Obstetrics and Gynecology (NFOG).

Report this publication


Seen <100 times